Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $126.49

Moderna, Inc. (NASDAQ:MRNA) has been given an average recommendation of “Hold” by the sixteen analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $129.55.

Several analysts have commented on the company. HSBC reiterated a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair reissued a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Royal Bank of Canada boosted their target price on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Finally, Canaccord Genuity Group raised their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday.

Insiders Place Their Bets

In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now owns 2,026,931 shares in the company, valued at $224,827,186.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at $224,827,186.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James M. Mock sold 647 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock worth $14,822,576 in the last three months. 15.20% of the stock is owned by company insiders.

Institutional Trading of Moderna

A number of large investors have recently added to or reduced their stakes in MRNA. Allworth Financial LP increased its holdings in shares of Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the last quarter. TIAA Trust National Association grew its holdings in Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the last quarter. Principle Wealth Partners LLC raised its position in Moderna by 4.3% in the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock worth $266,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC lifted its stake in Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after purchasing an additional 115 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Moderna by 32.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 2.3 %

NASDAQ:MRNA opened at $122.13 on Thursday. The stock has a market cap of $46.81 billion, a price-to-earnings ratio of -7.79 and a beta of 1.57. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $105.61 and a 200-day moving average price of $94.76. Moderna has a 12 month low of $62.55 and a 12 month high of $142.79.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s revenue was down 91.0% on a year-over-year basis. During the same period last year, the company posted $0.19 EPS. Equities analysts predict that Moderna will post -7.47 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.